Lehner T, Lyne C
Br Med J. 1969 Oct 18;4(5676):138-41. doi: 10.1136/bmj.4.5676.138.
Plasma cortisol (hydrocortisone) levels were measured in 42 subjects before and during administration of topical oral corticosteroids. Topical administration of 0.3-0.4 mg. of betamethasone disodium phosphate daily caused partial suppression of adrenal function in 8 out of 10 subjects tested. The adrenal function remained normal in 14 patients treated with 10 mg. of hydrocortisone hemisuccinate daily for periods of up to three years. Betamethasone 17-valerate also failed to cause adrenal suppression in doses of 0.4 mg. per day in 17 patients. The adrenal glands failed to respond normally to stimulation with Synacthen (tetracosactrin) in selected subjects with depressed plasma cortisol levels. Therapeutic doses of topical oral hydrocortisone hemisuccinate and betamethasone 17-valerate may be used in adults with oral lesions without fear of affecting adrenal function. Betamethasone disodium phosphate, however, should be avoided, as it may cause adrenal suppression.
对42名受试者在局部口服皮质类固醇给药前及给药期间测量了血浆皮质醇(氢化可的松)水平。每日局部给予0.3 - 0.4毫克磷酸倍他米松二钠,在10名受试对象中有8名出现肾上腺功能部分抑制。14名患者每日接受10毫克半琥珀酸氢化可的松治疗长达三年,其肾上腺功能仍保持正常。17名患者每日给予0.4毫克戊酸倍他米松,也未导致肾上腺抑制。在血浆皮质醇水平降低的特定受试者中,肾上腺对合成促肾上腺皮质激素(二十四肽促皮质素)刺激反应异常。局部口服半琥珀酸氢化可的松和戊酸倍他米松的治疗剂量可用于患有口腔病变的成人,不用担心影响肾上腺功能。然而,应避免使用磷酸倍他米松二钠,因为它可能导致肾上腺抑制。